Related Experiment Video
Updated: Sep 29, 2026

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Early Experience With Evoque Transcatheter Tricuspid Valve Replacement in Carcinoid Heart Disease
Jackson S Burton1,2, Ben Peterson2, Brian Whisenant2
1Department of Medicine, Division of Cardiovascular Medicine, University of Utah, Salt Lake City, Utah, USA.
Abstract:
Tricuspid regurgitation (TR) is nearly universal in carcinoid heart disease (CHD), but surgical replacement carries significant risk, and CHD was excluded from the landmark TRISCEND II trial. We present seven patients with CHD undergoing Evoque transcatheter tricuspid valve replacement (TTVR) at two tertiary centers. All achieved procedural success with TR reduced to mild or less and NYHA improvement at median 9-month follow-up. Two patients experienced intraoperative carcinoid crisis; one required salvage in-Evoque Sapien S3 deployment. Four patients demonstrated improvement in RV basal diameter. Evoque TTVR is feasible in CHD, but operators must anticipate unique anatomic challenges and carcinoid crisis risk.
Related Concept Videos
Cardiac Catheterization II: Right Heart Catheterization
Cardiac Catheterization III: Left Heart Catheterization
Mitral Regurgitation I: Introduction
Mitral Stenosis I: Introduction
Mitral Valve Prolapse I: Introduction
Aortic Regurgitation I: Introduction
